IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza to Develop, Manufacture U.S. Biopharma Firm’s Antibody Drug Conjugate

12:01 AM MDT | September 27, 2012 | Deepti Ramesh

Lonza says that biopharmaceutical company Intellect Neurosciences (New York) has awarded the future development and manufacture of the antibody-drug conjugate Conjumab-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s Conjumab-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease, Lonza says. Intellect is engaged in the discovery and...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa